Interleukin-2 therapy for refractory and relapsing lymphomas.

摘要: Recombinant interleukin-2 (rIL-2) has been reported to be active in metastatic renal cell carcinoma and malignant melanoma. The purpose of this trial was determine the efficacy toxicity rIL-2 administered continuous infusion patients with Hodgkin's disease (HD) non-Hodgkin lymphoma (NHL). 21 HD (4 patients), diffuse large-cell NHL (7) or low-grade (10) failure relapse after multiple-conventional treatments were included trial. therapy consisted an induction period two cycles separated by 3 weeks rest, and, absence progressive undue toxicity, a maintenance 4 monthly cycles. Each cycle comprised rIL-2: 18 × 106 IU/m2 per day on days 1–5 12–16. 1–5. Among treated patients, 5 (all those NHL) responded phase (1 complete response, partial responses) 2 had mixed response. Conversely, no response observed NHL. median duration months. as well tolerated most received full dosage, management did not require intensive care. During period, experienced grade III cardiovascular toxicity. interrupted 1 patient because myocardial infarction. This confirms inefficacy for treatment HD. NHL, activity needs explored further studies. may have place early disease, when immune system is compromised, adjuvant residual order improve